NanoViricides, Inc
NanoViricides, Inc is a biotechnology company focused on the development of nanoviricide antiviral drugs for the treatment of viral infections.
Business. NanoViricides, Inc (NNVC.K) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NYSE. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Its business activities focus on pharmaceuticals and medical research.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NanoViricides, Inc (NNVC.K) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NYSE. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. Its business activities focus on pharmaceuticals and medical research.
NanoViricides, Inc has a market capitalization of $37.58 million and a price-to-book ratio of 3.53, indicating that the market is valuing the company at a premium to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. The company's liquidity position is strong, with a current ratio of 4.32 and $3.26 million in cash and equivalents.
The company's profitability metrics are negative, with a return on equity of -17.41% and a return on assets of -16.18%, indicating that it is not generating returns for shareholders or asset holders. The company reported a net loss of $1.85 million and an operating loss of $1.91 million in the latest period. The EV/EBITDA ratio is negative at -17.98, reflecting the company's unprofitable operations.
NanoViricides, Inc does not provide segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure. The company's operations are likely focused on the development of antiviral drugs, with no disclosed geographic diversification.
The company's growth trajectory is not clearly defined in the available data. The company has not provided forward-looking revenue guidance, and the available financial data does not include historical revenue growth rates. The company is currently in a development phase, with no disclosed revenue-generating products.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution risk, with no dilutive events identified in the latest filings. The company's capital structure is currently debt-free, and there is no indication of near-term dilution pressure.
Recent events for NanoViricides, Inc include analyst price targets ranging from $6.00 to $6.00, with a mean and median price target of $6.00. The company has received one "Buy" recommendation and no "Strong Buy" or "Hold" recommendations from analysts.
- NanoViricides, Inc is a biotechnology company with a market capitalization of $37.58 million and a price-to-book ratio of 3.53.
- The company has a conservative capital structure with no long-term debt and a debt-to-equity ratio of 0.0.
- The company is unprofitable, with a return on equity of -17.41% and a return on assets of -16.18%.
- The company has a strong liquidity position, with a current ratio of 4.32 and $3.26 million in cash and equivalents.
- Analysts have assigned a mean price target of $6.00, with one "Buy" recommendation and no "Strong Buy" or "Hold" recommendations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income −8,5% YoY; Net income −9,5% YoY.
- ▍Operating income −8,5% YoY
- ▍Net income −9,5% YoY
- ▍Free cash flow −14,0% YoY
Operating income +43,3% YoY; Net income +42,9% YoY.
- ▍Operating income +43,3% YoY
- ▍Net income +42,9% YoY
- ▍Free cash flow +41,7% YoY
Operating income -$2.4M.
- ▍Operating income -$2.4M
Operating income -$1.9M.
- ▍Operating income -$1.9M
Operating income +4,8% YoY; Net income +3,4% YoY.
- ▍Operating income +4,8% YoY
- ▍Net income +3,4% YoY
- ▍Free cash flow +3,8% YoY
Operating income +7,2% YoY; Net income +8,1% YoY.
- ▍Operating income +7,2% YoY
- ▍Net income +8,1% YoY
- ▍Free cash flow +7,8% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- NanoViricides, Inc Market data — financials · 2026-05-28
- NanoViricides, Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 4.43xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.11xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 30.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 6.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 6.0%Derived (calculated)
- Shareholders' equity (annual): USD 11.07MSEC XBRL filing
- Cash & equivalents (annual): USD 5.15MSEC XBRL filing
- Total assets (annual): USD 12.27MSEC XBRL filing
- Current liabilities (annual): USD 1.2MSEC XBRL filing
- Total liabilities (annual): USD 1.2MSEC XBRL filing
- Current assets (annual): USD 5.3MSEC XBRL filing
- Shares outstanding (annual): 21.6MSEC XBRL filing
- Operating income (YoY) (2025-06-30 vs 2024-06-30): -12.6%Derived (calculated)
- Capex (YoY) (2025-06-30 vs 2024-06-30): -63.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 10.0%Derived (calculated)
- Net income (YoY) (2025-06-30 vs 2024-06-30): -14.1%Derived (calculated)
- EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 10.0%Derived (calculated)
- Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -34.3%Derived (calculated)
- R&D expense (YoY) (2025-06-30 vs 2024-06-30): 2.1%Derived (calculated)
- Total operating expenses (annual): USD 9.59MSEC XBRL filing
- Net income (annual): USD -9.47MSEC XBRL filing
- Capex (annual): USD 56.96KSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing